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Background-—Previous studies report conﬂicting results about a higher incidence of ventricular arrhythmias in patients with a
chronic total coronary occlusion (CTO). We aimed to investigate this association in a large cohort of implantable cardioverter
deﬁbrillator patients with long-term follow-up.
Methods and Results-—All consecutive patients from 1992 onwards who underwent implantable cardioverter deﬁbrillator
implantation for ischemic cardiomyopathy at the Leiden University Medical Center were evaluated. Coronary angiograms were
reviewed for the presence of a CTO. The occurrence of ventricular arrhythmias and survival status at follow-up were compared
between patients with and patients without a CTO. A total of 722 patients constitute the study cohort (age 6611 years; 84%
males; 74% primary prevention, median left ventricular ejection fraction 30% [ﬁrst–third quartile: 25–37], 44% received a cardiac
resynchronization therapy deﬁbrillator). At baseline, 240 patients (33%) had a CTO, and the CTOs were present for at least 44
(2–127) months. The median follow-up duration was 4 (2–6) years. On long-term follow-up, CTO patients had a higher crude
appropriate device therapy rate (37% versus 27%, P=0.010) and a lower crude survival rate (51% versus 67%, P<0.001) compared
with patients without a CTO. Corrected for baseline characteristics including left ventricular ejection fraction, the presence of a
CTO was an independent predictor for appropriate device therapy.
Conclusions-—The presence of a CTO in implantable cardioverter deﬁbrillator patients was associated with more appropriate
device therapy and worse prognosis at long-term follow-up. Further investigation is warranted regarding a potential beneﬁcial
effect of CTO revascularization on the incidence of ventricular arrhythmias. ( J Am Heart Assoc. 2018;7:e008609. DOI: 10.
1161/JAHA.118.008609.)
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T he presence of a chronic total coronary occlusion (CTO)has been associated with a worse prognosis compared
with patients with multivessel disease (MVD) without a CTO or
single-vessel disease (SVD).1 This has been reported both in
the setting of stable coronary artery disease and in
ST-segment elevation myocardial infarction patients, with or
without cardiogenic shock.2–4 The underlying mechanism for
this poorer prognosis is currently incompletely understood.
Additionally, sudden cardiac death appears to occur more
frequently in the long term in patients with a nonrevascular-
ized CTO compared with patients with a revascularized CTO.5
Furthermore, in patients with ischemic systolic heart failure
(ejection fraction ≤35%), the presence of a CTO has been
associated with an increased 2-year mortality.6
One of the hypotheses is that a CTO has a malicious
inﬂuence on cardiac electrical stability, which makes patients
with a CTO more prone to ventricular arrhythmias (VA),1,7
leading to a higher mortality rate. There are limited data on
the presence of a CTO and a higher incidence of VA in small
From the Department of Cardiology, Heart Center, Academic Medical Center –
University of Amsterdam, The Netherlands (I.M.v.D., J.E., B.E.P.M.C., R.D.,
R.E.K., A.A.M.W., J.P.S.H.); Department of Cardiology, Leiden University
Medical Center, Leiden, The Netherlands (D.Y., L.v.E., M.J.S.).
*Dr van Dongen and Dr Yilmaz contributed equally to this work.
Correspondence to: Jose P. S. Henriques, MD, PhD, Department of
Cardiology, Academic Medical Center – University of Amsterdam, Meibergdreef
9, 1105 AZ Amsterdam, The Netherlands. E-mail: j.p.henriques@amc.uva.nl
Received January 11, 2018; accepted March 9, 2018.
ª 2018 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is properly cited.
DOI: 10.1161/JAHA.118.008609 Journal of the American Heart Association 1
ORIGINAL RESEARCH
D
ow
nloaded from
 http://ahajournals.org by on August 14, 2019
implantable cardioverter-deﬁbrillator (ICD) patient popula-
tions, and reports are limited to short-term follow-up.8–10
The aim of the current eCTOpy-in-ICD (evaluation of the
impact of a Chronic Total coronary Occlusion on ventricular
arrhythmias and long-term mortality in patients with ischemic
cardiomyopathy and an Implantable Cardioverter-Deﬁbrillator)
study was to investigate this association in a larger cohort of
ICD patients with long-term follow-up, and to ﬁnd variables
associated with the occurrence of higher VA rates in CTO
patients compared with patients without a CTO.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Patient Population
All consecutive patients from the year 1992 onward who
underwent ICD implantation for primary or secondary pre-
vention at the Leiden University Medical Center and had
known ischemic heart disease were evaluated. Patient
baseline characteristics, ICD-related and clinical follow-up
were prospectively collected in the departmental Cardiology
Information System (EPD-vision; Leiden University Medical
Center, Leiden, The Netherlands). Indications for the ICD
implantations were at the treating physician’s discretion
according to international guidelines.11 All data for this study
have been collected during routine clinical practice. Therefore,
the institutional review board approved all data collection and
informed consent was waived by the Leiden University
Medical Center ethics committee.
Coronary Artery Disease Assessment
Coronary angiograms of all ICD patients were retrospectively
analyzed to identify patients with 1 or more CTOs. All
angiograms before the ICD implantation were considered
eligible as well as all angiograms performed within the ﬁrst
year after the ICD implantation, unless any coronary event
occurred from ICD implantation to angiogram. Preferably, the
most recent coronary angiogram before the ICD implantation
was used. A CTO was deﬁned as a total coronary artery
occlusion of 1 of the main arteries or large side-branches, with
thrombolysis in myocardial infarction (TIMI) 0 ﬂow and an
assumed duration of ≥3 months (based on prior angiograms/
prior documented myocardial infarction in the area of the
CTO). In case of the presence of a CTO, the location of the CTO
was recorded in a database following a 16-segment subdivi-
sion of the coronary artery tree.12 Any additional lesions were
also recorded in the database, and MVD was deﬁned as a
lesion >50% in, or previous percutaneous coronary interven-
tion (PCI) of, or coronary artery bypass grafting (CABG) of 2 or
more main coronary arteries or large side-branches (ie,
diagonal branch or obtuse marginal branch).
Additionally, the quality of collaterals to the CTO was
assessed using the Rentrop grade system.13 Of the CTO
patients who underwent revascularization (either PCI or
CABG), surgery reports and PCI angiograms were assessed
to investigate whether or not the CTO lesion was successfully
revascularized. In case of successful CTO revascularization
before the ICD implantation, the patient was allocated to the
non-CTO group. In case of (re)occlusion of the CTO lesion or
bypass, the patient was placed in the CTO group.
Device Implantation, Programming, and Device
Interrogation
All devices that were used were manufactured by Biotronik
(Berlin, Germany), Boston Scientiﬁc (Natick, MA), Medtronic
(Minneapolis, MN), or St. Jude Medical (St Paul, MN). A single-
chamber ICD, or a dual-chamber ICD, or a Cardiac Resynchro-
nization Therapy Deﬁbrillator (CRT-D) was implanted.14 Follow-
ing implantation, sensing and pacing thresholds were tested,
and a deﬁbrillation threshold test was performed. At the start of
the data collection for the registry, up until the year 2000, most
devices were programmed with a single zone in which shocks
were programmed to terminate VA >185 beats/min. From
2004 onward, the devices were programmed with 3 zones: VA
with a frequency from 150 to 188/190 were detected in a
monitoring zone and no therapy was programmed (30–32
Clinical Perspective
What Is New?
• In a large cohort of patients with an implantable cardioverter
deﬁbrillator for ischemic cardiomyopathy, the presence of a
chronic total coronary occlusion is associated with higher
mortality and more appropriate device therapy rates, and
chronic total coronary occlusion revascularization may
inﬂuence this association positively.
What Are the Clinical Implications?
• When clinicians encounter a patient with a chronic total
coronary occlusion, with or without an implantable car-
dioverter deﬁbrillator, they should be aware of a potentially
higher ventricular arrhythmia occurrence in these patients,
and chronic total coronary occlusion revascularization and/
or implantable cardioverter deﬁbrillator therapy should be
considered carefully for improving survival and patient
burden.
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intervals were needed for detection [NID] or 8/10 with a 2.5-s
initial delay, depending on the manufacturer).14 VA with a
frequency >188/190 per minute were detected in the ventric-
ular tachycardia (VT) zone, programmed with 2 to 4 bursts of
antitachycardia pacing to terminate the VA, followed by shock if
the VA persists (22–30 intervals needed for detection or 8/10
with a 2.5-s initial delay, depending on the manufacturer). The
ﬁnal zone was programmed to detect VA >220 to 231 beats/
min, in which shock was the ﬁrst therapy (12–30 intervals
needed for detection or 8/10 with a 1.0-s initial delay,
depending on themanufacturer).14 From 2008 to 2009 onward,
antitachycardia pacing was programmed during charging in the
last zone, depending on the manufacturer. Furthermore,
supraventricular tachycardia discriminators were enabled, and
atrial arrhythmia detection was set to >170 beats/min.14
Follow-Up
Periodic follow-up visits were performed every 3 to 6 months.
During follow-up visits, patients were clinically assessed, and
devices were interrogated. During this device interrogation,
stored episodes were analyzed and deﬁbrillator interventions
were registered. Device therapy was classiﬁed on the basis of
intracardiac electrograms and was considered appropriate
only when occurring in response to VT or ventricular
ﬁbrillation (VF). All other triggers for therapy were considered
inappropriate.
In the case of emigration or transmigration resulting in
referral to centers far from the primary center, or when follow-
up visits were not performed for ≥12 months, follow-up was
considered incomplete. These patients were censored in the
analysis at last known date of contact. In the case of heart
transplantation or premature termination of ICD treatment,
follow-up was ended at the time of intervention. Patients who
did not reach any end point remained at risk until the end of
the study. Survival status was retrieved from regularly updated
municipal civil registries. In all deceased patients, the cause of
death was retrieved from hospital letters or follow-up reports if
present, and otherwise from the general practitioner.
End Points and Deﬁnitions
The end points of interest for this study were the occurrence
of appropriate device therapy (as a substitute for VA
occurrence) and all-cause mortality, hypothesizing that in
the CTO group these end points would occur more often.
Appropriate device therapy was deﬁned as shock or anti-
tachycardia pacing for VF/VT. Therapy delivered for anything
other than VT or VF was deﬁned as inappropriate. Additionally,
(patient and coronary) variables associated with the
Figure 1. Flow diagram of patient inclusion. CTO indicates chronic total coronary occlusion; ICD,
implantable cardioverter deﬁbrillator; ICMP, ischemic cardiomyopathy; LUMC, Leiden University Medical
Center.
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occurrence of appropriate device therapy and all-cause
mortality were identiﬁed. Furthermore, we investigated the
impact of a CTO on end points in patients with an ICD for
primary as compared with secondary prevention, the role of
collateral vessels to the CTO, and the inﬂuence of SVD and
MVD with or without a CTO on outcomes. At baseline, we
calculated an adjusted MADITII (Multicenter Automatic
Deﬁbrillator Implantation Trial II) risk score for all patients.
The previously published MADITII risk score15 entails pres-
ence of New York Heart Association functional class >II, atrial
ﬁbrillation at baseline, a QRS duration of >120 ms, age
>70 years, and blood urea nitrogen >26 mg/dL. Presence of
any of these variables was scored as 1, and per patient a total
risk score was calculated (with a maximum score of 5). Since
blood urea nitrogen is not used regularly in the clinical setting
in The Netherlands, we used creatinine level >1.3 lmol/L
Table 1. Patient Baseline Characteristics
Overall (n=722) CTO (n=240) Non-CTO (n=482) P Value
Age, y 6611 6710 6511 0.019
Male 605 (84%) 208 (87%) 397 (82%) 0.163
Diabetes mellitus 194 (27%) 75 (31%) 119 (25%) 0.009
Hypertension 334 (46%) 115 (51%) 219 (48%) 0.466
Hypercholesterolemia 327 (45%) 133 (55%) 194 (40%) 0.001
Family history of CVD 270 (37%) 90 (38%) 180 (37%) 0.295
Family history of SCD 37 (5%) 11 (5%) 26 (5%) 0.568
Creatinine clearance 73 [52–99] 70 [50–95] 76 [55–100] 0.019
History of CABG 268 (37%) 86 (36%) 182 (38%) 0.424
ICD indication 0.031
Primary prevention 531 (74%) 164 (68%) 367 (76%)
Secondary prevention 191 (27%) 76 (32%) 115 (24%)
ICD type 0.383
Single- or dual chamber 402 (56%) 128 (53%) 274 (57%)
CRT-D 320 (44%) 112 (47%) 208 (43%)
AFl/AF 218 (30%) 67 (28%) 151 (31%) 0.390
LVEF 30% [25–37] 30% [22–35] 31% [26–38] 0.001
QRS duration, ms 120 [100–150] 120 [104–156] 117 [100–150] 0.029
Medication use
b-Blocker 504 (70%) 158 (66%) 346 (72%) 0.103
Sotalol 79 (11%) 21 (9%) 58 (12%) 0.207
Calcium antagonist 77 (11%) 30 (13%) 47 (10%) 0.306
Amiodarone 111 (15%) 45 (19%) 66 (14%) 0.080
Digoxin 55 (8%) 17 (7%) 38 (8%) 0.767
Documented age CTO, mo  43.7 [2.1–127.3]  
MADITII risk score* 0.070
0 157 (22%) 40 (17%) 117 (24%)
1 178 (25%) 54 (23%) 124 (26%)
2 167 (23%) 69 (29%) 98 (20%)
3 128 (18%) 45 (19%) 83 (17%)
4 65 (9%) 23 (10%) 42 (9%)
5 27 (4%) 9 (4%) 18 (4%)
AF indicates atrial ﬁbrillation; AFl, atrial ﬂutter; CABG, coronary artery bypass graft; CRT-D, cardiac resynchronization therapy deﬁbrillator; CTO, chronic total coronary occlusion; CVD, cardiovascular
disease; ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; MADITII, Multicenter Automatic Deﬁbrillator Implantation Trial II; SCD, sudden cardiac death.
*Adjusted: creatinine level >1.3 lmol/L instead of blood urea nitrogen level >26 mg/dL.
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instead, which does not inﬂuence the sensitivity of the risk
score as assessed by the developers of the risk score.15
Statistical Analysis
Continuous variables are depicted as mean (SD) or median
(interquartile range), and comparisons between groups were
made using independent t test or nonparametric tests, respec-
tively. Categorical variables are depicted as frequencies (per-
centage of total), and comparisons between groups were made
with the Fisher exact test or v2 test when applicable. All-cause
mortality event rates within groups are depicted with Kaplan–
Meier curves, and were compared using the log-rank test.
Kaplan–Meierestimates for10-year follow-upwerederived from
the analyses, and depicted as the estimate rates with SE. Cox
proportional hazards regression was used to assess the
predictive value of variables on outcomes, after visual veriﬁca-
tion of the proportionality assumption. Appropriate variables
were included after backward stepwise selection, excluding
variables with a P>0.10. For appropriate device therapy, the left
ventricular ejection fraction (LVEF) was forced into the multi-
variate model since it is a known strong predictor for device
therapy. Overall, a P value of <0.05 was considered statistically
signiﬁcant. All analyseswereperformedusingSPSS (Version24;
IBM Corp., Armonk, NY).
Results
Inclusion and Patient Population
In total, the cohort consisted of 722 patients with an ICD for
ischemic cardiomyopathy (ICM) for whom an angiography was
available (see Figure 1 for the ﬂow diagram). Of these 722
patients, 275 (38%) had a CTO before the ICD implantation
and 35 (13%) of these patients underwent CTO treatment
(either PCI or CABG) before the ICD implantation, resulting in
a total number of 240 patients (33%) with a conﬁrmed CTO at
the time of ICD implantation. Fifty-nine of these patients (25%)
had >1 CTO at baseline. The median time between date of the
angiography used for CTO identiﬁcation and date of ICD
implantation was 1 (0.4–15) week. The median documented
duration of the CTOs (age of the CTOs) was 44 (2–127)
months.
The baseline patient and angiographic characteristics are
shown in Tables 1 and 2. Patients in the CTO group were older,
more frequently had diabetes mellitus and hypercholes-
terolemia, had a lower creatinine clearance, had a lower LVEF,
had a longer QRS duration, and more frequently had MVD
comparedwith patients without a CTO. Also, in CTOpatients the
ICD indication was more often secondary prevention. Type of
device did not differ between patients with a CTO and the non-
CTO patients. The MADITII risk score showed a trend towards
more CTO patients with risk scores 1 and 2, and more non-CTO
patients with a risk score of 0.
Long-Term Outcomes
On long-term follow-up, with a median duration of 4 (2–6)
years, the overall crude cumulative event rates in this ICD
population were 30% for appropriate device therapy and 39%
for all-cause mortality. Both appropriate device therapy and
all-cause mortality occurred more frequently in the CTO
group, compared with the non-CTO group (37% versus 27%,
P=0.010, and 49% versus 33%, P<0.001, respectively)
(Table 3).
Figure 2 shows the Kaplan–Meier curves for appropriate
device therapy and survival, comparing patients with and
without a CTO. The 10-year appropriate device therapy
Kaplan–Meier estimates were 55 (SE 5)% for patients with a
CTO and 43 (SE 4)% for patients without a CTO. The Kaplan–
Meier estimates for 10-year survival were 26 (SE 5)% for
Table 2. Angiographic Baseline Characteristics
Overall
(n=722)
CTO
(n=240)
Non-CTO
(n=482) P Value
CTO vessel 
LAD  68 (28%) 
RCx  48 (20%) 
RCA  124 (52%) 
Proximal
location CTO
 133 (55%)  
Max collateral
Rentrop

Grade 0  37 (15%) 
Grade 1  101 (42%) 
Grade 2  60 (25%) 
Grade 3  33 (14%) 
Unknown  9 (4%)
Type of
collateral
filling

Bridge  28 (12%) 
Retrograde  145 (60%) 
Both  21 (9%) 
Vessel
disease (VD)
<0.001
1VD 187 (26%) 34 (14%) 153 (32%)
2VD 205 (28%) 62 (26%) 143 (30%)
3VD 330 (46%) 144 (60%) 186 (39%)
CTO indicates chronic coronary total occlusion; LAD, left anterior descending coronary
artery; RCA, right coronary artery; RCx, ramus circumﬂexus coronary artery.
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patients with a CTO and 42 (SE 4)% for patients without a
CTO, and the Kaplan–Meier estimates for other time points
are shown in Table 4.
On long-term follow-up, corrected for baseline patient and
angiographic characteristics such as LVEF, the presence of a
CTO was an independent predictor for appropriate device
therapy (hazard ratio 1.394; 95% conﬁdence interval, 1.060–
1.832; 0.018) and there was a trend for higher all-cause
mortality (hazard ratio 1.269; 95% conﬁdence interval, 0.996–
1.616; P=0.054) (Tables 5 and 6).
Inﬂuence of Primary Prevention Versus
Secondary Prevention
Irrespective of whether the ICD was implanted for primary or
secondary prevention, CTO patients had worse survival com-
paredwithnon-CTOpeers.Primarypreventionpatientswithouta
CTO experienced the lowest appropriate device therapy rate,
compared with primary prevention patients with a CTO and
secondary prevention patients (Figure 3).
Current Available Data
In Figure 4A and 4B, an overview of the available event rates for
all-cause death and appropriate device therapy of all studies on
this subject is depicted.8–10 Event rateswere numerically higher
in CTO patients with an ICD for ICM, compared with patients
without a CTO.
Inﬂuence of SVD, MVD, and CTO
Patients with SVD without a CTO experienced the lowest rate
of appropriate device therapy over time, followed by patients
with MVD without a CTO, compared with patients with a CTO
(Figure 5). Furthermore, patients with SVD with or without a
CTO had the highest survival rate compared with patients with
MVD and a CTO (Figure 5).
Inﬂuence of Collaterals
In patients with a CTO, the presence of well-developed
collaterals did not seem to inﬂuence long-term survival nor
appropriate device therapy compared with patients with
poorly developed collaterals (Figure 6).
CTO Revascularization
A small proportion of the CTO patients in this cohort was
revascularized before the ICD implantation (n=35), mainly
because of myocardial viability, inducible arrhythmias in the
CTO territory, or severe CAD for which CABG was indicated.
Patients with a revascularized CTO had similar appropriate
device therapy rates compared with patients without a CTO
(n=447) (Figure 7). Regarding long-term survival, patients
with a revascularized CTO had similar survival rates
compared with patients with a CTO (Figure 7).
Location of the CTO Lesion
Appropriate device therapy rates were similar between
patients with a CTO in the right coronary artery, left anterior
descending coronary artery, or ramus circumﬂexus coronary
artery (Figure 8). Survival was highest in patients with a CTO
in the ramus circumﬂexus coronary artery (Figure 8).
Table 3. Cumulative Crude Long-Term Event Rates
Overall (n=722) CTO (n=240) Non-CTO (n=482) P Value
All-cause mortality 279 (39%) 118 (49%) 161 (33%) <0.001
Cause of death, n (%) of observed deaths 0.538
Tachyarrhythmic 8 (2.9%) 3 (3%) 5 (3%)
Bradyarrhythmic 2 (1%) 1 (1%) 1 (1%)
Heart failure 73 (26%) 26 (22%) 47 (29%)
SCD 6 (2%) 1 (1%) 5 (3%)
Cardiovascular 28 (10%) 13 (11%) 15 (9%)
Appropriate device therapy 219 (30%) 88 (37%) 131 (27%) 0.010
ATP 155 (71%) 64 (73%) 91 (70%) 0.651
Shock 132 (60%) 53 (60%) 79 (60%) 1.000
Time-to-first appropriate device therapy in years 2.8 [1.0–5.2] 2.3 [0.9–4.4] 3.1 [1.1–5.6] 0.019
VT ablation 12 (2%) 5 (2%) 7 (2%) 0.555
ATP indicates antitachypacing; CTO, chronic total coronary occlusion; SCD, sudden cardiac death; VT, ventricular tachycardia.
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Discussion
The current study showed that on long-term follow-up,
patients with an ICD for ischemic heart disease who also
have a CTO (1) received more appropriate device therapy and
(2) had a higher all-cause mortality, compared with ICD
patients with ICM but without a CTO; (3) corrected for several
baseline characteristics (including age, LVEF, and QRS
duration). The presence of a CTO was an independent
predictor for more appropriate device therapy in this speciﬁc
patient population.
Currently Available Data
Previous published studies8–10,16,17 have shown a trend
towards higher appropriate device therapy and all-cause
mortality rates in ICD patients with a CTO. Also, the presence
of a CTO has proven to be associated with a worse survival
compared with patients with SVD or MVD without a CTO.3,4 The
current, substantially larger, study conﬁrms this observation.
Regarding appropriate device therapy, Nombela-Franco et al
found that patients with an ICD for ICM and a CTO experience
more device therapy both in primary (n=162) and secondary
Figure 2. Kaplan–Meier curves for freedom from death (A) and appropriate device therapy (B),
comparing patients with and without a CTO. CTO indicates chronic total coronary occlusion.
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(n=425) prevention.9,10 We have also observed this in our
cohort, suggesting that the presence of a CTO has more impact
on the myocardium than 1 or more narrowed coronary arteries.
In the COMMIT-HF (Contemporary Modalities in Treatment of
Heart Failure) substudywith patientswith ischemic systolic heart
failure (n=675), the presence of a CTO (n=278) was associated
with an increased 2-year all-cause mortality compared with
patients without a CTO (n=397). Also, 1-year cardiovascular
mortality and 1-year major adverse cardiovascular event rates
were signiﬁcantly higher in the groupof patientswith aCTO,6 and
(corrected for LVEF) the presence of a CTO was independently
associated with a higher 1-year mortality.
The cause of the high death rate in CTO patients, despite the
presence of an ICD, remains unclear. In our cohort this does
not appear to be driven by a higher occurrence of, for example,
untreatable VAs in the patients with a CTO. It could be
postulated that an ICD does decrease mortality from VAs, but
that CTO patients have a higher mortality because of the
presence of other comorbidities, such as diabetes mellitus. In
addition, when looking at the MADITII risk score (which was
developed in a primary prevention population post myocardial
infarction) in our population,15 a trend towards less CTO
patients with risk score 0 and more CTO patients with risk
scores of 1 and 2 can be appreciated. In the MADITII
population,15 these risk score groups were at lower risk for
mortality. Furthermore, in a large portion of all deaths in our
cohort, the exact cause was unknown. Hypothetically, these
CTO patients could have died more frequently from arrhythmic
causes untreatable by an ICD, which would be unknown since
their deaths would most likely have been ruled as from natural
causes and the ICD would not have been read out postmortem.
The pathophysiology of VAs is important and accordingly,
the cause of the CTO could be just as important. Di Marco
et al have shown that the presence of a CTO in a previous
infarcted area (infarct-related artery [IRA]-CTO) is associated
with the occurrence of more VA (especially fast VT/VF) and
more ICD therapy.18,19 VT ablation could be an appropriate
treatment option in these patients. Nevertheless, Di Marco
et al have also shown that the presence of an infarct-related
artery–CTO is an independent predictor of VT recurrence after
VT ablation, compared with patients with prior myocardial
infarction without an infarct-related artery–CTO.20
Table 4. Kaplan–Meier Estimates for Appropriate Device Therapy and All-Cause Mortality Rates at Several Time Points
Appropriate Device Therapy All-Cause Mortality
CTO (n=240) No-CTO (n=482) P Value CTO (n=240) No-CTO (n=482) P Value
1-y follow-up 15.8% 11.2% 0.103 7.4% 7.3% 0.982
3-y follow-up 36.0% 22.6% 0.003 25.1% 16.5% 0.020
5-y follow-up 46.8% 32.8% 0.002 41.9% 27.8% 0.001
CTO indicates chronic total coronary occlusion.
Table 5. Inﬂuence of Patient and Angiographic Characteristics on All-Cause Mortality
Characteristic
Univariate Multivariate
HR 95% CI P Value HR 95% CI P Value
Age 1.052 1.038–1.065 <0.001 1.050 1.036–1.064 <0.001
Male sex 0.878 0.634–1.215 0.433 
Hypertension 1.124 0.883–1.429 0.342 
Hypercholesterolemia 1.126 0.871–1.454 0.365 
Diabetes mellitus 1.682 1.309–2.162 <0.001 1.573 1.222–2.025 <0.001
Creatinine clearance 1.000 1.000–1.000 0.794 
QRS duration 1.001 1.000–1.001 <0.001 1.001 1.000–1.001 <0.001
LVEF 0.980 0.970–0.989 <0.001 0.982 0.972–0.991 <0.001
CTO 1.544 1.217–1.958 <0.001 1.269 0.996–1.616 0.054
Primary prevention 0.853 0.662–1.099 0.218 
MVD 1.899 1.395–2.586 <0.001 1.562 1.145–2.131 0.005
CI indicates conﬁdence interval; CTO, chronic coronary total occlusion; HR, hazard ratio; LVEF, left ventricular ejection fraction; MVD, multivessel disease.
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Most CTOs are infarct-related artery–CTOs,1 so this could
mean that in CTO patients most likely a larger infarct zone is
present, leading to more VTs. Combined with a reduced
ischemia reserve (during stress, exercise), leading to more VF,
the CTO could be a strong substrate for more arrhythmias. In
the eCTOpy-in-ICD population more appropriate therapy was
observed in the CTO group, because of both more VT and
more VF, compared with the non-CTO group.
Collaterals
The inﬂuence of collateral vessels to a CTO has been
investigated sparsely. One registry showed that the pres-
ence of well-developed collaterals to a concomitant CTO in
ST-segment elevation myocardial infarction patients was
associated with better long-term survival.21 In our cohort of
stable ICD patients, we found no clear effect of the quality
Figure 3. Inﬂuence on long-term outcomes of the presence of a CTO in primary and secondary prevention. CTO indicates chronic total
coronary occlusion.
Table 6. Inﬂuence of Patient and Angiographic Characteristics on Appropriate Device Therapy
Characteristic
Univariate Multivariate
HR 95% CI P Value HR 95% CI P Value
Age 1.017 1.004–1.030 0.013 1.013 1.00–1.026 0.055
Male sex 1.901 1.200–3.011 0.006 1.757 1.107–2.787 0.017
Hypertension 1.051 0.800–1.380 0.723 
Hypercholesterolemia 0.930 0.701–1.234 0.616 
Diabetes mellitus 0.845 0.614–1.163 0.302 
Creatinine clearance 1.000 1.000–1.000 0.224 
QRS duration 1.000 1.000–1.001 0.302 
LVEF 1.000 0.997–1.002 0.750 0.999 0.989–1.008 0.801
CTO 1.529 1.166–2.005 0.002 1.394 1.060–1.832 0.018
Primary prevention 0.516 0.393–0.679 <0.001 0.548 0.416–0.723 <0.001
MVD 1.273 0.931–1.743 0.131 
CI indicates conﬁdence interval; CTO, chronic coronary total occlusion; HR, hazard ratio; LVEF, left ventricular ejection fraction; MVD, multivessel disease.
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of collateral vessels on survival or on appropriate device
therapy, although appropriate device therapy appeared to
occur more frequently in patients with well-developed
collaterals. In the VACTO secondary (impact of chronic
total coronary occlusion on recurrence of ventricular
arrhythmias in ischemic secondary prevention implantable
cardioverter-deﬁbrillator recipients) study, a trend towards
more appropriate therapy was observed in patients with
Rentrop 3 collaterals.9 The authors hypothesize that
hibernating myocardium may explain this ﬁnding.9 In
patients with good collateral ﬁlling of the CTO vessel,
more viability could be present, especially in a border zone
around the necrotic core of the area affected by the CTO.9
This hypothesis has been underscored in a cardiac
magnetic resonance imaging study of patients in the
EXPLORE (Evaluating xience and left ventricular function
in PCI on occlusions after STEMI) trial (ST-segment
elevation myocardial infarction patients with a concurrent
CTO [n=302]). Patients with well-developed collaterals
showed an improved restoration of dysfunctional segments
in the CTO territory, compared with patients with poorly
developed collaterals.22 In addition, Werner et al showed
that few patients with well-developed collaterals show a
normal coronary ﬂow reserve, which suggests that even in
these patients episodes of ischemia can occur, which would
be a trigger for VA.9,23
Primary Versus Secondary Prevention in
Combination With a CTO
The presence of a CTO results in higher all-causemortality rates
in patients with an ICD for ICM for both primary and secondary
Figure 4. A, Overview of all-cause mortality rates (%) per study. B, Overview of cumulative appropriate ICD
therapy rates (%) per study. eCTOpy-in-ICD indicates evaluation of the impact of a Chronic Total coronary
Occlusion on ventricular arrhythmias and long-termmortality in patients with ischemic cardiomyopathy and an
Implantable Cardioverter-Deﬁbrillator (this study); FU, follow-up; ICD, implantable cardioverter deﬁbrillator;
VACTO, impact of chronic total coronary occlusion on recurrence of ventricular arrhythmias in ischemic
secondary prevention implantable cardioverter-deﬁbrillator recipients (study).
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Figure 5. Inﬂuence on long-term outcomes of single-vessel disease, multivessel disease, and presence of a CTO. CTO indicates chronic total
coronary occlusion; MVD, multivessel disease; SVD, single-vessel disease.
Figure 6. Inﬂuence on long-term outcomes of poorly developed vs well-developed collaterals.
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prevention. ThepresenceofaCTOhas,however, a lessabundant
effect on appropriate device therapy in secondary prevention
patients in the long term. However, the relatively lower number
of secondary prevention patients in our cohort (n=191) could
have played a role in this observed difference. On the Kaplan–
Meier curve, at 2-year follow-up a clear divergence of the
Figure 7. Inﬂuence on long-term outcomes of CTO revascularization. CTO indicates chronic total coronary occlusion.
Figure 8. Inﬂuence of location of the CTO lesion. CTO indicates chronic total coronary occlusion; LAD, left anterior descending coronary
artery; RCA, right coronary artery; RCx, ramus circumﬂexus coronary artery.
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appropriate therapy rates in the secondary prevention patients
withaCTOcanbeobserved.Thiscoincideswith theobservations
made in theVACTOsecondary study. In their population (n=425)
of secondary prevention patients, the presence of a CTO was
associated with, and was an independent predictor for, both
decreased survival and more appropriate therapy.9
Treatment of a CTO
Since it has been established that patients with a CTO
experience more VAs and have a lower life expectancy, one of
the most signiﬁcant questions is whether CTO revasculariza-
tion can improve outcomes. In general registry populations of
patients with a CTO, CTO revascularization seems to improve
outcomes.1,24 Regarding patients with an ICD for ICM and a
CTO, little is known about the effect of revascularization. Raja
et al compared patient groups without a CTO, with a CTO, and
with a revascularized CTO. Their analyses did not show any
statistical differences between the 3 groups.16 Yap et al
looked at outcomes in a small subgroup (n=25) of out of
hospital cardiac arrest patients with a CTO, and found that
compared with patients with an unrevascularized CTO, event
rates were similar. The current study showed that appropriate
device therapy rates in patients undergoing CTO revascular-
ization (n=35) before ICD implantation were similar to the
rates found in the non-CTO group (n=447). The currently
limited available data is thus conﬂicting with regard to the
question of whether CTO revascularization inﬂuences the
increased occurrence of VAs in CTO patients, but our data
might suggest that CTO revascularization could improve
electrical stability and reduce appropriate device therapy,
which is a heavy burden for ICD patients. In addition, one
could question the need for an ICD in patients with a
successfully revascularized CTO.
In a systematic review and meta-analysis of studies investi-
gating the effect of CTO revascularization on ECG parameters,
we found that directly after successful revascularization, several
ECG parameters improved compared with before CTO
revascularization.7 However, in most of the included studies in
this review, no clinical follow-up datawere available.7 Therefore,
whether CTO revascularization truly ameliorates ventricular
arrhythmogenicity remains unclear. Furthermore, what type of
CTO revascularization shouldbepreferred (CTO, PCI, orCABG) is
also unknown.
Limitations
This study has several limitations that should be taken into
account when interpreting the data. First, this study is a registry
study,withallassociated limitations. Importantly,becauseof the
retrospective nature of this study, there is a lack of insight into
reasons whether or not to revascularize the diagnosed CTOs.
Also, in some of the patients the exact cause of death could no
longer be determined, and since in The Netherlands it is not
customary to read out the ICD postmortem, no information on
arrhythmias premortem was available. Second, for some
subanalyses the numbers are low, so these analyses should be
considered purely as hypothesis generating.
Conclusion
The current study shows that in a large cohort of patients with
an ICD for ICM, the presence of a CTO is associated with more
appropriate device therapy and worse survival at long-term
follow-up, compared with patients without a CTO. Moreover,
the presence of a CTO in patients with an ICD is an
independent predictor for the occurrence of VAs leading to
more appropriate device therapy. CTO revascularization might
ameliorate this negative effect of a CTO on the myocardium.
Disclosures
None.
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